Study of AVZO-021 in Patients With Advanced Solid Tumors

This study tests AVZO-021, a new targeted therapy, in people with advanced hormone receptor-positive/HER2-negative breast cancer, ovarian cancer, or other specific solid tumors with a particular genetic amplification (CCNE1), either alone or in combination with other drugs. **You may be eligible if...** - You are 18 or older in good general condition (ECOG 0–1) - You have advanced or metastatic HR+/HER2- breast cancer that has progressed after prior CDK4/6 inhibitor and hormonal therapy, OR - You have advanced ovarian, peritoneal, or fallopian tube cancer with a CCNE1 gene amplification that is resistant to platinum-based chemotherapy, OR - You have another solid tumor with CCNE1 amplification and no remaining effective standard treatment - Standard therapies are no longer effective or safe for you **You may NOT be eligible if...** - Effective standard treatment options are still available to you - You do not have the required genetic profile or cancer type - You have serious organ dysfunction, active brain metastases, or are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.